Hidden compliance risks for life sciences companiesThe life sciences industry has some unique challenges when it comes to compliance. But if you think third Share XHidden compliance risks for life sciences companieshttps://pharmaphorum.com/views-and-analysis/hidden-compliance-risks-for-life-sciences-companies/
Not just COVID-19 vaccines: 5 things that cause blood clotsReports of COVID-19 vaccinations causing blood clots has caused alarm in the general population. However due to the Share XNot just COVID-19 vaccines: 5 things that cause blood clotshttps://pharmaphorum.com/views-and-analysis/5-things-that-cause-blood-clots/
The role of data science and text mining in the search for new therapiesToday, most drug discovery programmes begin with the identification and validation of disease modifying biological targets. The primary Share XThe role of data science and text mining in the search for new therapieshttps://pharmaphorum.com/views-and-analysis/text-mining-new-therapies/
What comes next: digital transformation in B2B life sciences salesAs the contours of a post-pandemic world begin to take shape, those working B2B sales in the life Share XWhat comes next: digital transformation in B2B life sciences saleshttps://pharmaphorum.com/sales-marketing/what-comes-next-digital-transformation-in-b2b-life-sciences-sales/
Three pillars of post-pandemic launch excellenceIQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity Share XThree pillars of post-pandemic launch excellencehttps://pharmaphorum.com/views-and-analysis/three-pillars-of-post-pandemic-launch-excellence/
Cytisinicline – the solution to stop smoking?Whether present in electronic or combustible cigarettes, nicotine is a highly addictive substance. Dr Cindy Jacobs, chief medical Share XCytisinicline – the solution to stop smoking?https://pharmaphorum.com/views-and-analysis/the-need-for-nicotine-vaping-cessation-therapies/
The power of communication: engaging diverse groups in healthcareHumans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to Share XThe power of communication: engaging diverse groups in healthcarehttps://pharmaphorum.com/views-and-analysis/the-power-of-communication-engaging-diverse-groups-in-healthcare/
The next generation of immunotherapy? Innate Pharma targets NK cellsClinical-stage oncology biotech Innate Pharma is on a mission to harness the power of natural killer cells to Share XThe next generation of immunotherapy? Innate Pharma targets NK cellshttps://pharmaphorum.com/views-and-analysis/the-next-generation-of-immunotherapy-innate-pharma/
Merck’s Keytruda demonstrates adjuvant use in kidney cancerMerck & Co has announced interim data from its pivotal Phase 3 KEYNOTE-564 trial evaluating immunotherapy Keytruda for Share XMerck’s Keytruda demonstrates adjuvant use in kidney cancerhttps://pharmaphorum.com/news/mercks-keytruda/
